Corline Biomedical

The Outcome

Coreline was granted € 2.3M from the SME Instrument, HORIZON 2020, phase 2.

The Company

Corline, founded in 1991, develops, manufactures and markets heparin based solutions to improve kidney transplantation, cell therapies and applications in the evolving field of regenerative medicine. Using the same heparin technology platform - CHC™ - Corline also provides best-in-class surface coatings, making medical device implants blood and biocompatible.

The project

This project will validate the safety and efficancy of Corline Biomedical’s pharmaceutical compound Renaparin®, a novel cell replacement technology used to coat the lining of the blood vessels of kidneys prior to transplantation. Donor kidneys lack natural blood flow while awaiting transplantation. This can lead to ischemia (a shortage of oxygen and glucose supply to the kidney tissue). Renaparin® is used when the kidney has been extracted from the donor and is stored in preservation solution awaiting transplantation. There, it binds to, replaces, repairs and protects damaged kidney cells on the endothelium of the vascular wall. As a result, a kidney is less likely to activate the host’s innate immune system, which increases the chances of organ survival and substantially reduces the likelihood of organ rejection. The activities proposed in this project will bring Renaparin® through a Phase I/IIa clinical trial in humans.

GAEU's role

GAEU has been deeply involved in structuring the scope and configuration of the project and its budget. GAEU conducted workshops with the client and wrote the successful SME Instrument phase 2 application. GAEU also produced the Grant Agreement and reported the project to the EC. 


“This is absolutely fantastic for Corline! This grant is one of the highest allocations awarded to a Swedish life science company within SME Instrument and it will allow us to fully fund our entire clinical study on Renaparin®. Apart from the purely practical and economic implications, it is also a great recognition of our project. It is really encouraging that the European Commission has recognized the potential in our project. With this grant, we will be able to create a platform from which we can accelerate Corline’s growth in kidney transplantation and new indications. GAEU Consulting has been our advisor throughout the entire application process and wrote our grant application. The outstanding application scoring received is proof to the quality of their service. I highly recommend GAEU as Horizon 2020 advisors for Life Science companies.” Henrik Nittmar, PhD CEO

Henrik Nittmar, PhD CEO